Viking Therapeutics, Inc. (VKTX)
| Market Cap | 5.74B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -99.15M |
| Shares Out | 111.44M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,479,409 |
| Open | 52.70 |
| Previous Close | 51.51 |
| Day's Range | 50.40 - 53.04 |
| 52-Week Range | 11.21 - 99.41 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 109.80 (+113.08%) |
| Earnings Date | Oct 23, 2024 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is $109.8, which is an increase of 113.08% from the latest price.
News
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
On Tuesday, Viking Therapeutics, Inc. VKTX highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred t...
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
The biotech's liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class Profile Highlighted by Robust...
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Results to be Featured in Oral Late Breaker Presentation SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focus...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.
Viking Therapeutics soars then drops on obesity data
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector.
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results
Viking Therapeutics (VKTX) shares fell Monday, handing back early gains, as analysts questioned the path ahead for its developmental weight-loss drugs even after news of upbeat results in clinical tri...
Dow Jones, S&P 500 slip ahead of US elections; NVIDIA, Viking Therapeutics rise while Talen Energy declines
US stocks slumped on Monday as investors eagerly waited for the outcome of the US Presidential election on Tuesday. At the time of writing, the Dow Jones Industrial Average slid 175 points, or 0.4%, ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results...
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
TSLA Stalls on China Sales, CEG Sells Off, VKTX's Promising Weight Loss Drug Trial
After Tesla's (TSLA) earnings ripped the stock to the upside, lower-than-expected EV sales in China continued a notable downtrend since its report. Constellation Energy (CEG) sold off when its guidanc...
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics Inc VKTX announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024.
Should you buy Viking Therapeutics (VKTX) after today's spike?
Viking Therapeutics (NASDAQ: VKTX) saw its stock surge over 10% in pre-market trading on November 4, following the release of highly encouraging early-stage results for its experimental obesity drug, ...
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations.
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Rel...
Viking Therapeutics stock jumps after ‘great' trial of weight-loss drug
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
Viking Therapeutics: Lots Of Positives
Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment due to its potential in a $40 billion market. The company plans to escalate V...
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO , Oct. 28, 2024 /PRNewswire/ -- Viking Therap...
Viking Therapeutics: Q3 Earnings Report Loads A Barrage Of Catalysts
Viking Therapeutics shows significant clinical progress in obesity, NASH, and X-ALD, with promising Phase II and preclinical data positioning it for potential market leadership. Despite operating at a...
S&P 500, Nasdaq rise sharply ending 3-day losing streak; Viking Therapeutics surge, while Capri's shares slump
US benchmark equity averages rose on Friday as the market ended a three-day losing streak. At the time of writing, the Dow Jones Industrial Average was up 0.3%, while S&P 500 rose 0.8% from the previ...
Viking Therapeutics' shares soar on fresh weight-loss medication hopes
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking's stock jumping on weight-loss hopes.
Viking Therapeutics' stock soars 18% as data on oral weight-loss drug looms
Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings th...